13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001582844
Total reported value
$143.5M
$143.5M
33 檔
35.5%
In Q2 2024, Acuta Capital Partners, LLC's U.S. equity holdings reached a combined market value of $143.5M, distributed across 33 disclosed stock positions.
During Q2 2024, Acuta Capital Partners, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | OCUL | Ocular Therapeutix Inc | Stock-Other | 15.98% | +0.07% | +5.15% | |
| 2 | ELVN | Enliven Therapeutics Inc | Stock-Other | 7.83% | — | +0.40% | |
| 3 | PCVX | Vaxcyte Inc | Stock-Other | 7.03% | — | +5.31% | |
| 4 | DYN | Dyne Therapeutics Inc | Stock-Other | 6.32% | — | +15.18% | |
| 5 | PRAX | Praxis Precision Medicines I | Stock-Other | 5.73% | -0.13% | +1.31% | |
| 6 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 5.10% | — | +72.37% | |
| 7 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 4.54% | — | -23.38% | |
| 8 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 4.40% | +1.27% | -30.07% | |
| 9 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 4.35% | -1.80% | EXIT | |
| 10 | INSM | Insmed Inc | Stock-Healthcare | 4.07% | — | +16.82% | |
| 11 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 3.66% | — | -57.14% | |
| 12 | TRML | Tourmaline Bio Inc | Stock-Other | 2.92% | — | +3.26% | |
| 13 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 2.86% | — | +42.41% | |
| 14 | KURA | Kura Oncology Inc | Stock-Other | 2.83% | — | +81.11% | |
| 15 | ✓ | Mersana Therapeutics Inc | Stock-Other | 2.82% | — | -23.17% | |
| 16 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 2.46% | — | — | |
| 17 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 2.28% | +6.59% | — | |
| 18 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.19% | — | — | |
| 19 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 2.12% | -18.59% | EXIT | |
| 20 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 2.05% | — | +70.15% | |
| 21 | ACLXGBX | Arcellx Inc | Stock-Other | 1.96% | — | +22.32% | |
| 22 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 1.53% | — | — | |
| 23 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.45% | +0.60% | — | |
| 24 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.65% | — | — | |
| 25 | CELC | Celcuity Inc | Stock-Other | 0.62% | — | — | |
| 26 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 0.57% | — | -7.69% | |
| 27 | PLRX | Pliant Therapeutics Inc | Stock-Other | 0.42% | — | — | |
| 28 | RAPP | Rapport Therapeutics Inc | Stock-Other | 0.39% | — | — | |
| 29 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.36% | — | — | |
| 30 | CYPH | Cypherpunk Technologies Inc | Stock-Other | 0.32% | — | -44.94% | |
| 31 | CLRBUSD | Cellectar Biosciences Inc | Stock-Other | 0.15% | — | -50.87% | |
| 32 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 0.01% | — | — | |
| 33 | SVRA | Savara Inc | Stock-Other | — | — | — |
According to official SEC Form 13F filings, Acuta Capital Partners, LLC reported a total U.S. public equity portfolio value of $143.5M across 33 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including OCUL, ELVN, PCVX) accounted for 35.5% of total reported equity market value during Q2 2024.
During Q2 2024, Acuta Capital Partners, LLC's top holdings by market value included OCUL (16.0%)、ELVN (7.8%)、PCVX (7.0%). The largest single position, OCUL, represented 16.0% of total portfolio value.
In Q2 2024, Acuta Capital Partners, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.